Swing Trading Plan
Expected figures are probability-weighted from our historical pattern database; Trade R:R is measured from the entry, target and stop levels.
Current Setup
ABVX is forming a double-bottom reversal pattern with perfect structure score of 15.0. The stock bounced from support at $83.55 and is now trading at $91.44, positioned between key support and resistance at $100.08. Breakout score of 9.75 and volume score of 10.91 indicate moderate confirmation—current volume at 738,764 shares is tracking 83% of the 20-day average. RSI at 51.71 shows neutral momentum without overbought conditions. The pattern quality aggregates to an overall score of 68.66 with 67.18% win probability, suggesting a technically sound setup primed for the measured move target of $95.77.
Stock Context
On November 10, 2026, Abivax presented obefazimod data at the Guggenheim Healthcare Innovation Conference, positioning the drug as a potential new standard in inflammatory bowel disease. The company reported 50% endoscopic remission at the end of maintenance in ulcerative colitis, described as unusually strong across trials. Abivax completed a $920 million public offering in July 2026 and received positive pre-NDA FDA interaction on July 30, 2026. The company holds €402.4 million in cash and short-term investments as of June 30, 2026. Goldman Sachs launched coverage with a Buy rating and $155 target. This recent positive catalysts—FDA interaction, strong Phase 3 data, and bullish analyst initiation—align with the timing of the double-bottom formation and explain why the pattern is emerging now amid biotech sector momentum.
What to Expect
A successful breakout through $100.08 resistance would validate the double-bottom reversal, targeting the conservative measurement of $95.77 initially, with potential for continuation toward $105–110 based on measured move projection. Volume confirmation requires daily volume trending back toward or exceeding the 894,609-share 20-day average; the current 83% relative volume is adequate but not compelling. Invalidation occurs decisively below $83.55 support, where the pattern would fail. With win probability at 67.18%, historical data suggests roughly two-thirds of similar double-bottom setups in biotech resolve in the bullish direction, though execution risk remains material.
Risk Factors
Execution risks remain around regulatory approval, manufacturing, spending, and launch preparation. Abivax reported a net loss of €165.9 million in H1 2026 with R&D expenses of €107.9 million. Wedbush cut its price target to $118 and kept a Neutral rating, arguing that the 2026 NDA filing and possible 2027 approval are already priced in. The stock's 3-month performance of -24.71% shows recent weakness despite positive catalysts, signaling distribution risk. Beta at 0.59 provides some downside protection, but biotech sector volatility at 51.61% over 20 days creates headline risk. An NDA rejection or adverse competitive development could shatter the pattern. Monitor for analyst downgrades or guidance revisions through the planned December investor presentations.
How We Find and Score This Setup
We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.
What the terms mean →
Frequently Asked Questions
Is ABVX a good swing trade?
ABVX scored 69 out of 98 on our double bottom scan, with a 67% historical win probability over a 2-7 trading days hold. Moderate setup based on our systematic scoring.
What is the entry, target, and stop loss for this setup?
The setup's reference price is $91.44, with a conservative target of $95.77 and a stop loss at $81.20.
What would invalidate this double bottom setup?
A close below the stop loss at $81.20 would invalidate the setup and suggest the pattern has failed.
How is the win probability calculated?
Win probability is a calibrated estimate of how similar historical double bottom setups performed over the following 10 trading days, drawn from a database of 370,000+ historical pattern detections across 6,000+ NYSE and NASDAQ stocks.